


A



B





Figure 1

A



B



C



Figure 2




A**B****C**

Figure 3

A



B



C




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11

09320320 - 032301




Figure 12

09320320 • 032604




Figure 13




Figure 14

403230-0020200





Figure 15

A



B




Figure 16




Figure 17

09820320 - 032604




Figure 18




Figure 19

006320 320 - 032804




Figure 20




Figure 21

F03330-0202360




Figure 22




Figure 23




Figure 24

CD - Markers β - Actin


CD 10



CD 13



CD 56



CF - SkM

NHDF

PAL #3

CF - SkM

NHDF

PAL #3

Figure 25




Figure 26




Figure 27




Figure 28




Figure 29

CD - Markers

β - Actin

CD34



CD90



CF - SkM

二
HDF

PAL #3

CF - SkM

NIHDF

PAL #3

Figure 30





Figure 31 A-C

098203320 - 032801




Figure 32 A-Y




Figure 33 A-R




Figure 34




Figure 35




Figure 36




Figure 37




Figure 38




Figure 39




Figure 40

CT3F 46, XX
(17 year-old female dermal biopsy specimen)



Figure 41

in vitro aPPSC Differentiation on Matrigel
HS10-1%

Tube formation
12 hours 24 hours 2 days conditioned




Figure 42

in vitro aPPSC Differentiation on Matrigel

1% + VEGF
2 days conditioned

Time points:

12 hours

24 hours



Is it forming?

Figure 43

aPPSC Localization following Administration

1 wk after i.v. injection
to ischemic animal



Figure 44

Matrigel after 1 wk Condition

F D G a g 0 0 0 0 0 0 0 0 0




Figure 45

ELSC-derived Cells in Matrigel




Figure 46

ELSC-derived Cells in Matrigel




Figure 47

T 0 13 21 29 37 45 53 61

ELSC Transplantation into Hindlimb Ischemia

2 wks



Figure 48

ELSC Transplantation into Hindlimb Ischemia 2 wks




Figure 49

Muscle Organogenesis by ELSC in Hindlimb Ischemia



2wks





Figure 50

Muscle Organogenesis by ELS*C* in Hindlimb Ischemia



2wks




Figure 51

Organogenesis with Neovascularization by ELSC in Hindlimb Ischemia

2wks




Figure 52

CT3F-1(RT-PCR)




Figure 53

CT3F-2(RT-PCR)




Figure 54

Positive Control




Figure 55




Figure 56




Figure 57



Figure 58



Figure 59




Figure 60




Figure 61




Figure 62




Figure 63




Figure 64




Figure 65

0 9 8 7 6 5 4 3 2 1 0 - 1 2 3 4 5 6 7 8 9 1




Figure 66




Figure 67




Figure 68




Figure 69





Figure 70




Figure 71




Figure 72

Figure 73




Figure 74



Figure 75



Figure 76





Figure 77



0 9 8 7 6 5 4 3 2 1 0 9 8 7 6 5 4 3 2 1

Figure 78



"T" "E" "G" "E" "G" "O" "P" "G" "E" "G" "E" "G" "O"

Figure 79





Figure 80



0932700 "0932700"